Literature DB >> 9784088

Nicotine availability from Eclipse tobacco-heating cigarette.

J A Stapleton1, M A Russell, G Sutherland, C Feyerabend.   

Abstract

A cigarette which heats rather than burns tobacco (Premier) was introduced in 1988, but was unacceptable due to unpleasant taste and low nicotine intake. We examined availability of nicotine from a new version (Eclipse), in the same four subjects as our earlier Premier study. Average blood nicotine boosts of 23.7 and 17.8 ng/ml were obtained from smoking a first and second Eclipse. This substantially exceeds intake from Premier (boost 13 ng/ml) and that obtained by heavy smokers from conventional brands (boost 12-15 ng/ml). Eclipse (or similar product) may be the best option for averting Peto's dire warnings of rising millions of annual smoking deaths in the 2020s, and its potential for large-scale, long-term switching warrants further study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784088     DOI: 10.1007/s002130050719

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Estimating the health consequences of replacing cigarettes with nicotine inhalers.

Authors:  W Sumner
Journal:  Tob Control       Date:  2003-06       Impact factor: 7.552

2.  New tobacco products: do smokers like them?

Authors:  R S Caraballo; L L Pederson; N Gupta
Journal:  Tob Control       Date:  2006-02       Impact factor: 7.552

3.  Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit.

Authors:  K O Fagerström; J R Hughes; T Rasmussen; P W Callas
Journal:  Tob Control       Date:  2000-09       Impact factor: 7.552

Review 4.  Heated tobacco products for smoking cessation and reducing smoking prevalence.

Authors:  Harry Tattan-Birch; Jamie Hartmann-Boyce; Loren Kock; Erikas Simonavicius; Leonie Brose; Sarah Jackson; Lion Shahab; Jamie Brown
Journal:  Cochrane Database Syst Rev       Date:  2022-01-06

Review 5.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

6.  Permissive nicotine regulation as a complement to traditional tobacco control.

Authors:  Walton Sumner
Journal:  BMC Public Health       Date:  2005-02-24       Impact factor: 3.295

7.  Informing iQOS Regulations in the United States: A Synthesis of What We Know.

Authors:  Carla J Berg; Yael Bar-Zeev; Hagai Levine
Journal:  Sage Open       Date:  2020-01-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.